-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TJCLDN-4B in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TJCLDN-4B in Gastroesophageal (GE) Junction Carcinomas Drug Details: TJ-033721 is under development for the treatment...
-
Sector Analysis
NewPhilippines Beer and Cider Market Overview by Category, Price Segment Dynamics, Brand and Flavour, Distribution and Packaging, 2023
Philippines Beer and Cider Market Report Overview The Philippines beer and cider market size was LCU358.89 million in 2022. The market is expected to grow at a CAGR of more than 15% during 2023-2028. Philippines Beer and Cider Market Outlook, 2022-2028 (LCU Million) Buy the Full Report for More Insights into the Philippines Beer and Cider Market Forecast Download A Free Report Sample The Philippines Beer and Cider market research report provides detailed data analysis of the beer and cider...
-
Company Insights
NewAmerican Airlines Group – Digital Transformation Strategies
American Airlines Digital Transformation Strategies Report Overview  American Airlines is strengthening its focus on the use of key disruptive technologies to enhance its operations and provide better customer service. To do so, it is tapping into key disruptive technologies including AI, big data, blockchain, cloud, and fintech, among others. The annual ICT spending of American Airlines is estimated at $1.7 billion for 2023. a major share of this spending earmarked for software, hardware, network, and communications. American Airlines Group is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CAL-02 in Community-Acquired Bacterial Pneumonia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CAL-02 in Community-Acquired Bacterial Pneumonia Drug Details: CAL-02 (combioxin) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CAL-02 in Community Acquired Pneumonia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CAL-02 in Community Acquired Pneumonia Drug Details: CAL-02 (combioxin) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Transitional Cell Cancer (Urothelial Cell Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details:E-602 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Melanoma Drug Details:E-602 is under development for the treatment of solid tumors including melanoma,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Breast Cancer Drug Details:E-602 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Colorectal Cancer Drug Details:E-602 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab deruxtecan in Non-Small Cell Lung Cancer Drug Details: DS-1062 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Gastric Cancer Drug Details:E-602 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) Drug Details:Rezafungin acetate (Rezzayo) is a antifungal agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Pancreatic Cancer Drug Details:E-602 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Ovarian Cancer Drug Details:E-602 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Solid Tumor Drug Details:E-602 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Non-Small Cell Lung Cancer Drug Details:E-602 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMM-1104 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Solid Tumor Drug Details: IMM-1-104 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Head And Neck Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Head And Neck Cancer Drug Details:E-602 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – E-602 in Gastroesophageal (GE) Junction Carcinomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Gastroesophageal (GE) Junction Carcinomas Drug Details:E-602 is under development for the treatment of solid...
-
Sector Analysis
NewChina Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2028
China Defense Market Report Overview The China defense budget is worth $230.3 billion in 2023, and, is anticipated to register a CAGR of more than 6% during 2024-2028. Territorial claims in the South China Sea and the increasing strength and assertiveness of the US have spurred the Chinese government to enhance its military capabilities. The consequent demand for defense equipment will revolve around fighter and multirole aircraft, corvettes, infrastructure construction, submarines, naval vessels, and surveillance equipment. China Defense Market Outlook,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.